Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy

被引：4
|
作者：
Masquelier, Bernard [1 ]
Capdepont, Sophie
Neau, Didier
Peuchant, Olivia
Taupin, Jean-Luc
Coakley, Eoin
Lie, Yolanda
Carpentier, Wassila
Dabis, Francois
Fleury, Herve J. A.
机构：
[1] CHU Bordeaux, Dept Virol & Immunol Biol, Bordeaux, France
[2] CHU Bordeaux, Dept Malad Infect, Bordeaux, France
[3] Univ Victor Segalen, INSERM, U 593, ISPED, Bordeaux, France
[4] Monogram Biosci, San Francisco, CA USA
[5] INSERM, U543, Lab Immunol Cellulaire, Paris, France
来源：
AIDS | 2007年 / 21卷 / 01期
关键词：
D O I：
10.1097/QAD.0b013e3280117053
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We studied a case of recent infection with multidrug-resistant (MDR) HIV-1. Over 16 months off therapy, the CD4 cell count decreased from 419 to 184 cells/mu l. Antiretroviral therapy (ART) then led to an incomplete virological response but to an immunological benefit, concurrently with a shift to CCR5-only tropism and a reduction in replication capacity. ART, even if suboptimal, can be of interest in the case of MDR virus infection.
引用
收藏
页码：103 / 106
页数：4
相关论文
共 50 条
  • [21] Editorial comment: A plethora of options in multidrug-resistant HIV-1 infection
    Katzenstein, David A.
    AIDS READER, 2008, 18 (09): : 478 - 479
  • [22] A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection
    Coull, JJ
    Turner, D
    Melby, T
    Betts, MR
    Lanier, R
    Margolis, DM
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (05) : 423 - 434
  • [23] Microbicides for multidrug-resistant and multitropic HIV-1
    D'Cruz, Osmond J.
    Uckun, Fatih M.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (02) : 152 - 169
  • [24] Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection
    Hiryak, Kayla
    Koren, David E.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (06) : 792 - 797
  • [25] Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy
    Fox, J.
    Dustan, S.
    McClure, M.
    Weber, J.
    Fidler, S.
    HIV MEDICINE, 2006, 7 (07) : 477 - 483
  • [26] Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1
    Vigano, Alessandro
    Meroni, Luca
    Marchetti, Giulia
    Vanzulli, Angelo
    Giacomet, Vania
    Fasan, Silvia
    Pradello, Andrea
    Cerini, Chiaro
    Zuccotti, Gian V.
    ANTIVIRAL THERAPY, 2008, 13 (06) : 839 - 843
  • [27] Viral escape in the CNS with multidrug-resistant HIV-1
    Beguelin, Charles
    Vazquez, Miriam
    Bertschi, Manuel
    Yerly, Sabine
    de Jong, Denise
    Rauch, Andri
    Cusini, Alexia
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 156 - 157
  • [28] Differential coreceptor use by dual-tropic HIV-1 envelopes impacts coreceptor inhibitor susceptibility
    Toma, J.
    Whitcomb, J.
    Fransen, S.
    Reeves, J.
    Parkin, N.
    Petropoulos, C.
    Huang, W.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S113 - S113
  • [29] Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus
    Lee, Natalie E. E.
    Sutherland, Rebecca K. K.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2023, 36 (01) : 15 - 19
  • [30] Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5Δ32 allele
    Gorry, PR
    Zhang, CS
    Wu, S
    Kunstman, K
    Trachtenberg, E
    Phair, J
    Wolinsky, S
    Gabuzda, D
    LANCET, 2002, 359 (9320): : 1832 - 1834
12345